Morgan Stanley Assumes BeiGene, Ltd. (BGNE) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
BeiGene, Ltd. (BGNE) PT Raised to $207 at Bernstein SocGen Group
November 29, 2024 8:35 AM ESTBernstein SocGen Group analyst Rebecca Liang raised the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $207.00 while maintaining a Market Perform rating.
The analyst said: "In this model update of BeiGene post-earnings, we present a new, integrated B-cell malignancies market model covering... More
